BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38186305)

  • 1. Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker.
    Lundmark F; Vorobyeva A; Liu Y; Lindbo S; Xu T; Oroujeni M; Rinne SS; Rosenström U; Garousi J
    Mol Med Rep; 2024 Feb; 29(2):. PubMed ID: 38186305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
    Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
    J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein.
    Vorobyeva A; Oroujeni M; Lindbo S; Hober S; Xu T; Liu Y; Rinne SS; Garousi J
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32998229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual MVK cleavable linkers effectively reduce renal retention of
    Valpreda G; Trachsel B; Vogel V; Schibli R; Mu L; Behe M
    Bioorg Med Chem; 2022 Nov; 73():117040. PubMed ID: 36202066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
    Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR
    Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.
    Garousi J; von Witting E; Borin J; Vorobyeva A; Altai M; Vorontsova O; Konijnenberg MW; Oroujeni M; Orlova A; Tolmachev V; Hober S
    Biomaterials; 2021 Jan; 266():120381. PubMed ID: 33120197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
    Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
    Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels.
    Uehara T; Koike M; Nakata H; Hanaoka H; Iida Y; Hashimoto K; Akizawa H; Endo K; Arano Y
    Bioconjug Chem; 2007; 18(1):190-8. PubMed ID: 17226973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Efficient Method for Labeling Single Domain Antibody Fragments with
    Zhou Z; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioconjug Chem; 2018 Dec; 29(12):4090-4103. PubMed ID: 30384599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK.
    Trachsel B; Valpreda G; Lutz A; Schibli R; Mu L; Béhé M
    EJNMMI Radiopharm Chem; 2023 Sep; 8(1):21. PubMed ID: 37665477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity.
    Strand J; Nordeman P; Honarvar H; Altai M; Orlova A; Larhed M; Tolmachev V
    ChemistryOpen; 2015 Apr; 4(2):174-82. PubMed ID: 25969816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.
    Wilbur DS; Chyan MK; Hamlin DK; Nguyen H; Vessella RL
    Bioconjug Chem; 2011 Jun; 22(6):1089-102. PubMed ID: 21513347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
    Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
    Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of
    Bendre S; Zhang Z; Kuo HT; Rousseau J; Zhang C; Merkens H; Roxin Á; Bénard F; Lin KS
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32854201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Handling of
    Uehara T; Kanazawa N; Suzuki C; Mizuno Y; Suzuki H; Hanaoka H; Arano Y
    Bioconjug Chem; 2020 Nov; 31(11):2618-2627. PubMed ID: 33085454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
    Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
    Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evaluation of a New Series of Albumin-Binding
    Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR
    Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
    Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
    Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.
    Garousi J; Lindbo S; Honarvar H; Velletta J; Mitran B; Altai M; Orlova A; Tolmachev V; Hober S
    Bioconjug Chem; 2016 Nov; 27(11):2678-2688. PubMed ID: 27740752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.